Literature DB >> 29424022

Acenocoumarol as an alternative anticoagulant in a patient with warfarin-related nephropathy.

Sapan Kumar Behera1, Alphienes Stanley Xavier1, Sandhiya Selvarajan1, Hemachandren Munuswamy2, Satish Haridasan3, Bheemanathi Hanuman Srinivas4.   

Abstract

ADVERSE EVENT: Warfarin-related nephropathy. DRUG IMPLICATED: Warfarin. THE PATIENT: A 31-year-old female, managed with warfarin for rheumatic heart disease with atrial fibrillation. EVIDENCE THAT LINKS THE DRUG TO THE EVENT: There were no alternative causes of nephropathy that could have caused the adverse event in this patient. MANAGEMENT: Shifting the drug from warfarin to acenocoumarol. MECHANISM: Difference in renal elimination between warfarin and acenocoumarol. IMPLICATION FOR THERAPY: Clinicians should be aware of this rare adverse effect of warfarin, and acenocoumarol can be considered as an alternative therapy for this condition. HYPOTHESES TO BE TESTED: Further prospectively designed studies are needed to consider acenocoumarol as an alternative therapy in warfarin-related nephropathy.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29424022      PMCID: PMC5903245          DOI: 10.1111/bcp.13541

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  Acenocoumarol: A Review of Anticoagulant Efficacy and Safety.

Authors:  Abhijit Trailokya; J S Hiremath; Jps Sawhney; Y K Mishra; Vivek Kanhere; R Srinivasa; Mangesh Tiwaskar
Journal:  J Assoc Physicians India       Date:  2016-02

2.  Acenocoumarol as an alternative anticoagulant in a patient with warfarin-related nephropathy.

Authors:  Sapan Kumar Behera; Alphienes Stanley Xavier; Sandhiya Selvarajan; Hemachandren Munuswamy; Satish Haridasan; Bheemanathi Hanuman Srinivas
Journal:  Br J Clin Pharmacol       Date:  2018-02-28       Impact factor: 4.335

3.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

4.  Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases.

Authors:  Sergey V Brodsky; Anjali Satoskar; Jun Chen; Gyongyi Nadasdy; Jeremiah W Eagen; Mirza Hamirani; Lee Hebert; Edward Calomeni; Tibor Nadasdy
Journal:  Am J Kidney Dis       Date:  2009-07-04       Impact factor: 8.860

Review 5.  Anticoagulation-related nephropathy.

Authors:  D S Wheeler; R P Giugliano; J Rangaswami
Journal:  J Thromb Haemost       Date:  2016-02-15       Impact factor: 5.824

6.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

7.  Warfarin related acute kidney injury: A case report.

Authors:  S Mendonca; D Gupta; A Valsan; R Tewari
Journal:  Indian J Nephrol       Date:  2017 Jan-Feb

8.  The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in korean patients.

Authors:  Jung Nam An; Shin Young Ahn; Chang-Hwan Yoon; Tae-Jin Youn; Moon-Ku Han; Sejoong Kim; Ho Jun Chin; Ki Young Na; Dong-Wan Chae
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

Review 9.  Warfarin related nephropathy: a case report and review of the literature.

Authors:  Chee Yong Ng; Chieh Suai Tan; Chee Tang Chin; See Lim Lim; Ling Zhu; Keng Thye Woo; Puay Hoon Tan
Journal:  BMC Nephrol       Date:  2016-02-01       Impact factor: 2.388

Review 10.  Anticoagulants and acute kidney injury: clinical and pathology considerations.

Authors:  Sergey V Brodsky
Journal:  Kidney Res Clin Pract       Date:  2014-11-18
  10 in total
  3 in total

1.  Acenocoumarol as an alternative anticoagulant in a patient with warfarin-related nephropathy.

Authors:  Sapan Kumar Behera; Alphienes Stanley Xavier; Sandhiya Selvarajan; Hemachandren Munuswamy; Satish Haridasan; Bheemanathi Hanuman Srinivas
Journal:  Br J Clin Pharmacol       Date:  2018-02-28       Impact factor: 4.335

Review 2.  Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.

Authors:  Raminderjit Kaur; Manpreet Kaur; Jatinder Singh
Journal:  Cardiovasc Diabetol       Date:  2018-08-31       Impact factor: 9.951

3.  The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight.

Authors:  Pietro Scicchitano; Marco Tucci; Maria Consiglia Bellino; Francesca Cortese; Annagrazia Cecere; Micaela De Palo; Francesco Massari; Pasquale Caldarola; Francesco Silvestris; Marco Matteo Ciccone
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.